J2kbio

At a glance

J2kbio filed 17 disclosures in the last 12 months, including 2 insider. The most recent key filing was on Aug 26.

Revenue for 2025 was ₩33B, down 0.5% on 2024. Operating margin was 8.9% against 10.9% a year earlier. Debt was 13% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩26.7B and operating profit of ₩4.6B.

The 2025 annual report lists 59 employees with an average tenure of 3.3 years and average pay of ₩56.2M, #1160 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩181.9M each on average. It paid ₩250 per common share in cash dividends, against ₩200 a year earlier (+25%). 이재섭 and related parties held 62.03% at year end.

From the 2025 annual report

Staff: 59 (31 men, 28 women), of whom 2 on fixed-term contracts. Total pay for the year: ₩3.3B. Directors and auditors: 5, paid ₩909.6M in total.

Dividends (common shares)

Largest shareholder

이재섭 holds 24.65%; with 6 related parties the group holds 62.03% of common shares at year end (from 63.27% at the start of the year).

Auditor: 한울회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary